Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer

Alberto Ravaioli, Maurizio Marangolo, Enzo Pasquini, Andrea Rossi, Dino Amadori, Giorgio Cruciani, Davide Tassinari, Giovanni Oliverio, Petros Giovanis, Daniele Turci, Federica Zumaglini, Mario Nicolini, Ilaria Panzini

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer. Patients and Methods: Forty-five patients in this multicenter, open, nonrandomized study received oxaliplatin 130 mg/m2 on the first day of each course and 5-FU and LV 350 mg/m2 and 20 mg/m2, respectively, as a daily bolus for 5 days, every 21 days, for a maximum of six courses. Results: Partial responses occurred in 18 patients, giving an intent-to-treat response rate of 40.0%. Median time to response was 12.7 weeks; median duration of response was 18.4 weeks. Median progression-free survival was 5.9 months; median survival was 14 months. The independent prognostic factors for improved overall survival were good performance status and negative carcino-embryonic antigen blood level. Incidences of adverse effects were reduced after the 5-FU dose was reduced to 300 mg/m2. Reversible neurologic toxicity occurred in 44.4% of patients. Conclusion: Bolus administration of oxaliplatin, 5-FU, and LV as first-line therapy for untreated advanced colorectal cancer is efficacious and safe. In addition to a more favorable safety profile, the 300 mg/m2 dosage offered improved dose-intensity compared with the initial dosage.

Original languageEnglish
Pages (from-to)2545-2550
Number of pages6
JournalJournal of Clinical Oncology
Volume20
Issue number10
DOIs
Publication statusPublished - May 15 2002

Fingerprint

oxaliplatin
Leucovorin
Fluorouracil
Colorectal Neoplasms
Therapeutics
Survival
Nervous System
Disease-Free Survival
Appointments and Schedules
Safety
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ravaioli, A., Marangolo, M., Pasquini, E., Rossi, A., Amadori, D., Cruciani, G., ... Panzini, I. (2002). Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. Journal of Clinical Oncology, 20(10), 2545-2550. https://doi.org/10.1200/JCO.2002.08.144

Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. / Ravaioli, Alberto; Marangolo, Maurizio; Pasquini, Enzo; Rossi, Andrea; Amadori, Dino; Cruciani, Giorgio; Tassinari, Davide; Oliverio, Giovanni; Giovanis, Petros; Turci, Daniele; Zumaglini, Federica; Nicolini, Mario; Panzini, Ilaria.

In: Journal of Clinical Oncology, Vol. 20, No. 10, 15.05.2002, p. 2545-2550.

Research output: Contribution to journalArticle

Ravaioli, A, Marangolo, M, Pasquini, E, Rossi, A, Amadori, D, Cruciani, G, Tassinari, D, Oliverio, G, Giovanis, P, Turci, D, Zumaglini, F, Nicolini, M & Panzini, I 2002, 'Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer', Journal of Clinical Oncology, vol. 20, no. 10, pp. 2545-2550. https://doi.org/10.1200/JCO.2002.08.144
Ravaioli, Alberto ; Marangolo, Maurizio ; Pasquini, Enzo ; Rossi, Andrea ; Amadori, Dino ; Cruciani, Giorgio ; Tassinari, Davide ; Oliverio, Giovanni ; Giovanis, Petros ; Turci, Daniele ; Zumaglini, Federica ; Nicolini, Mario ; Panzini, Ilaria. / Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 10. pp. 2545-2550.
@article{8cf1a98dd41448029d6de1ffeb8aa235,
title = "Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer",
abstract = "Purpose: A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer. Patients and Methods: Forty-five patients in this multicenter, open, nonrandomized study received oxaliplatin 130 mg/m2 on the first day of each course and 5-FU and LV 350 mg/m2 and 20 mg/m2, respectively, as a daily bolus for 5 days, every 21 days, for a maximum of six courses. Results: Partial responses occurred in 18 patients, giving an intent-to-treat response rate of 40.0{\%}. Median time to response was 12.7 weeks; median duration of response was 18.4 weeks. Median progression-free survival was 5.9 months; median survival was 14 months. The independent prognostic factors for improved overall survival were good performance status and negative carcino-embryonic antigen blood level. Incidences of adverse effects were reduced after the 5-FU dose was reduced to 300 mg/m2. Reversible neurologic toxicity occurred in 44.4{\%} of patients. Conclusion: Bolus administration of oxaliplatin, 5-FU, and LV as first-line therapy for untreated advanced colorectal cancer is efficacious and safe. In addition to a more favorable safety profile, the 300 mg/m2 dosage offered improved dose-intensity compared with the initial dosage.",
author = "Alberto Ravaioli and Maurizio Marangolo and Enzo Pasquini and Andrea Rossi and Dino Amadori and Giorgio Cruciani and Davide Tassinari and Giovanni Oliverio and Petros Giovanis and Daniele Turci and Federica Zumaglini and Mario Nicolini and Ilaria Panzini",
year = "2002",
month = "5",
day = "15",
doi = "10.1200/JCO.2002.08.144",
language = "English",
volume = "20",
pages = "2545--2550",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer

AU - Ravaioli, Alberto

AU - Marangolo, Maurizio

AU - Pasquini, Enzo

AU - Rossi, Andrea

AU - Amadori, Dino

AU - Cruciani, Giorgio

AU - Tassinari, Davide

AU - Oliverio, Giovanni

AU - Giovanis, Petros

AU - Turci, Daniele

AU - Zumaglini, Federica

AU - Nicolini, Mario

AU - Panzini, Ilaria

PY - 2002/5/15

Y1 - 2002/5/15

N2 - Purpose: A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer. Patients and Methods: Forty-five patients in this multicenter, open, nonrandomized study received oxaliplatin 130 mg/m2 on the first day of each course and 5-FU and LV 350 mg/m2 and 20 mg/m2, respectively, as a daily bolus for 5 days, every 21 days, for a maximum of six courses. Results: Partial responses occurred in 18 patients, giving an intent-to-treat response rate of 40.0%. Median time to response was 12.7 weeks; median duration of response was 18.4 weeks. Median progression-free survival was 5.9 months; median survival was 14 months. The independent prognostic factors for improved overall survival were good performance status and negative carcino-embryonic antigen blood level. Incidences of adverse effects were reduced after the 5-FU dose was reduced to 300 mg/m2. Reversible neurologic toxicity occurred in 44.4% of patients. Conclusion: Bolus administration of oxaliplatin, 5-FU, and LV as first-line therapy for untreated advanced colorectal cancer is efficacious and safe. In addition to a more favorable safety profile, the 300 mg/m2 dosage offered improved dose-intensity compared with the initial dosage.

AB - Purpose: A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer. Patients and Methods: Forty-five patients in this multicenter, open, nonrandomized study received oxaliplatin 130 mg/m2 on the first day of each course and 5-FU and LV 350 mg/m2 and 20 mg/m2, respectively, as a daily bolus for 5 days, every 21 days, for a maximum of six courses. Results: Partial responses occurred in 18 patients, giving an intent-to-treat response rate of 40.0%. Median time to response was 12.7 weeks; median duration of response was 18.4 weeks. Median progression-free survival was 5.9 months; median survival was 14 months. The independent prognostic factors for improved overall survival were good performance status and negative carcino-embryonic antigen blood level. Incidences of adverse effects were reduced after the 5-FU dose was reduced to 300 mg/m2. Reversible neurologic toxicity occurred in 44.4% of patients. Conclusion: Bolus administration of oxaliplatin, 5-FU, and LV as first-line therapy for untreated advanced colorectal cancer is efficacious and safe. In addition to a more favorable safety profile, the 300 mg/m2 dosage offered improved dose-intensity compared with the initial dosage.

UR - http://www.scopus.com/inward/record.url?scp=0037093207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037093207&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.08.144

DO - 10.1200/JCO.2002.08.144

M3 - Article

VL - 20

SP - 2545

EP - 2550

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -